James B Duhadaway

List of Publications by Year
in descending order

54 papers	6,367 citations	126907 33 h-index	168389 53 g-index
55 all docs	55 docs citations	55 times ranked	7468 citing authors

#	Article	IF	Citations
1	The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. Journal of Immunology, 2022, 208, 571-581.	0.8	13
2	IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNÎ³/IL6 Balance to Promote Neovascularization. Cancer Immunology Research, 2021, 9, 514-528.	3.4	16
3	The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Molecular Cancer Therapeutics, 2021, 20, 2166-2176.	4.1	19
4	Peptide vaccination directed against IDO1-expressing immune cells elicits CD8⁺ and CD4⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. , 2020, 8, e000605.		34
5	Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology, 2020, 11, 1861.	4.8	70
6	Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry, 2019, 162, 455-464.	5.5	37
7	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	7.0	48
8	CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. Cancer Research, 2018, 78, 1657-1671.	0.9	97
9	Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clinical Immunology, 2017, 179, 8-16.	3.2	44
10	RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus. DMM Disease Models and Mechanisms, 2017, 10, 1313-1322.	2.4	7
11	Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Research, 2017, 77, 6795-6811.	0.9	433
12	IDO1 is an Integral Mediator of Inflammatory Neovascularization. EBioMedicine, 2016, 14, 74-82.	6.1	75
13	IDO2 Modulates T Cellâ€“Dependent Autoimmune Responses through a B Cellâ€“Intrinsic Mechanism. Journal of Immunology, 2016, 196, 4487-4497.	0.8	56
14	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. European Journal of Medicinal Chemistry, 2016, 108, 564-576.	5.5	33
15	Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Digestive Diseases and Sciences, 2016, 61, 423-432.	2.3	14
16	Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer. Oncotarget, 2016, 7, 7372-7380.	1.8	3
17	Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget, 2016, 7, 21812-21824.	1.8	7
18	IDO2 Is a Critical Mediator of Autoantibody Production and Inflammatory Pathogenesis in a Mouse Model of Autoimmune Arthritis. Journal of Immunology, 2014, 192, 2082-2090.	0.8	104

#	Article	IF	Citations
19	IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology, 2014, 26, 357-367.	4.0	168
20	Specific In Situ Detection of Murine Indoleamine 2, 3â€‹scp›D‹/scp›ioxygenase. Journal of Cellular Biochemistry, 2014, 115, 391-396.	2.6	8
21	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 2014, 511, 184-190.	27.8	574
22	The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Developmental Biology, 2013, 382, 160-171.	2.0	28
23	Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. Journal of Radiation Oncology, 2013, 2, 315-321.	0.7	52
24	RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis. Cancer Research, 2013, 73, 50-61.	0.9	38
25	Opposing Biological Functions of Tryptophan Catabolizing Enzymes During Intracellular Infection. Journal of Infectious Diseases, 2012, 205, 152-161.	4.0	121
26	IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. OncoImmunology, 2012, 1, 1460-1468.	4.6	338
27	IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery, 2012, 2, 722-735.	9.4	280
28	RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. Journal of Cellular Biochemistry, 2011, 112, 1572-1584.	2.6	34
29	Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biology and Therapy, 2011, 12, 1050-1058.	3.4	45
30	Genomic Profiling of miRNAs in Two Human Lens Cell Lines. Current Eye Research, 2010, 35, 812-818.	1.5	18
31	Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology, Immunotherapy, 2010, 59, 1655-1663.	4.2	57
32	Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase. Molecular Cancer Therapeutics, 2010, 9, 1864-1871.	4.1	27
33	Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate. Cancer Research, 2010, 70, 1845-1853.	0.9	65
34	The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity. Journal of Immunology, 2009, 182, 7509-7517.	0.8	111
35	Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase. Journal of Medicinal Chemistry, 2008, 51, 4968-4977.	6.4	148
36	Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 1706-1718.	6.4	151

#	Article	IF	Citations
37	Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17073-17078.	7.1	214
38	Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Research, 2008, 68, 1683-1690.	0.9	27
39	Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research, 2007, 67, 792-801.	0.9	557
40	Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. Cancer Research, 2007, 67, 100-107.	0.9	35
41	Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound <scp>d</scp>-1-Methyl-Tryptophan. Cancer Research, 2007, 67, 7082-7087.	0.9	453
42	RhoB Regulates PDGFR-Î² Trafficking and Signaling in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2597-2605.	2.4	60
43	Structureâ^'Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 684-692.	6.4	161
44	Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine, 2005, 11, 312-319.	30.7	998
45	Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochemical and Biophysical Research Communications, 2005, 336, 572-578.	2.1	16
46	Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition. Cancer Research, 2004, 64, 8389-8396.	0.9	22
47	Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology and Therapy, 2004, 3, 1236-1242.	3.4	23
48	Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: Diverse sites of nuclear expression and losses in prostate cancer. Journal of Cellular Biochemistry, 2003, 88, 635-642.	2.6	42
49	Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene, 2003, 22, 3578-3588.	5.9	21
50	Targeted Disruption of the Murine Bin1/Amphiphysin II Gene Does Not Disable Endocytosis but Results in Embryonic Cardiomyopathy with Aberrant Myofibril Formation. Molecular and Cellular Biology, 2003, 23, 4295-4306.	2.3	118
51	Loss of heterozygosity and tumor suppressor activity ofBin1 in prostate carcinoma. , 2000, 86, 155-161.		84
52	Bau, a Splice Form of Neurabin-I that Interacts with the Tumor Suppressor Bin1, Inhibits Malignant Cell Transformation. Cell Adhesion and Communication, 1999, 7, 99-110.	1.7	4
53	The MurineBin1Gene Functions Early in Myogenesis and Defines a New Region of Synteny between Mouse Chromosome 18 and Human Chromosome 2. Genomics, 1999, 56, 51-58.	2.9	28
54	Structural Analysis of the Human BIN1 Gene. Journal of Biological Chemistry, 1997, 272, 31453-31458.	3.4	124